Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
STOK
STOK
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
STOK News
Chair of Stoke Therapeutics Sells Shares
3d ago
NASDAQ.COM
Stoke Therapeutics Chair Sells 4,355 Shares of Stock
3d ago
Fool
Stoke Therapeutics Chair Sells Shares Worth $174K Amid 340% Stock Surge
3d ago
Yahoo Finance
Stoke Therapeutics Executive Sells Shares Amid Strong Performance
6d ago
Fool
Stoke Therapeutics Grants Stock Options to New Employees
Mar 17 2026
Newsfilter
Stoke and Biogen Release Zorevunersen Study Data
Mar 05 2026
NASDAQ.COM
Zorevunersen May Transform Dravet Syndrome Treatment, New Data Shows
Mar 04 2026
Globenewswire
Zorevunersen Shows Promise for Dravet Syndrome Treatment
Mar 04 2026
Newsfilter
Stoke Therapeutics Launches ADOA Treatment Study with STK-002
Feb 11 2026
Newsfilter
Analysis of Stoke Therapeutics Options Trading
Jan 30 2026
NASDAQ.COM
Stoke Therapeutics Secures New Headquarters in Waltham
Jan 27 2026
PRnewswire
Stoke Therapeutics Secures New Headquarters in Waltham for Growth and Research Expansion
Jan 27 2026
Newsfilter
Exelixis Reports Preliminary 2025 Revenue of $2.123 Billion, Shares Drop 4.6%
Jan 12 2026
Benzinga
Bark Inc (BARK) Shares Surge 19.9% on Acquisition Proposal from Great Dane
Jan 12 2026
Benzinga
Stoke Therapeutics Accelerates EMPEROR Study Timeline, Expects Patient Enrollment by Q2 2026
Jan 12 2026
NASDAQ.COM
Stoke Accelerates Dravet Syndrome Drug Development, Expects 150 Patient Enrollment by 2026
Jan 11 2026
Businesswire
Show More News
